Three-Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma.
Marcus Chun Jin Tan, Chee Wui Ong, Maria Cecilia Aquino, Katherine Wanxian Lun, Chelvin Cheryl Agnes Sng, Dawn Ka Ann Lim, Seng Chee Loon, Victor Teck Chang Koh, Paul Tec Kuan Chew
Summary
The PGI demonstrated sustained IOP reduction and a reduction of medication burden at 3 years postoperatively.
Abstract
PRCIS
In our case series, the 3-year failure for Paul Glaucoma Implant (PGI) implantation was 14.6%. At 3 years postoperatively, there was a significant reduction in mean intraocular pressure (IOP) and the number of glaucoma medications used.
OBJECTIVE
To determine the 3-year efficacy and safety of the PGI, a novel glaucoma tube shunt in patients with glaucoma.
METHODS
Retrospective review of all patients who had undergone PGI implantation in a single tertiary institution in Singapore between May 1, 2017 and January 1, 2022. Data were extracted from electronic health records (Computerized Patient Support System 2 and Epic). The primary outcome measure was failure, defined as IOP >18 mm Hg or <6 mm Hg on 2 consecutive visits after 3 months, reoperation for IOP-related indication, explantation of implant, or loss of light perception vision. Complete success was defined as the absence of failure without medications at 36 months, and qualified success similarly, but with medications. Postoperative mean IOP, mean number of IOP-lowering medications used, and visual acuity were also assessed.
RESULTS
Forty-eight eyes in 48 patients were identified. Thirty-one patients (64.6%) had primary open angle and angle closure glaucoma, and 18 (37.5%) had previous existing tube implants or trabeculectomy. At 3 years postoperatively, 7 cases (14.6%) fulfilled the criteria for failure and 36 (75%) met the criteria for complete success. The mean IOP at 36 months was 14.9 ± 4.11 mm Hg, from the mean preoperative IOP of 20.6 ± 6.13 mm Hg ( P < 0.001). The mean number of IOP-lowering medications used was reduced from 3.13 ± 0.959 preoperatively to 0.167 ± 0.476 at 36 months ( P < 0.001). The most common postoperative complication was hypotony (n = 17, 35.4%), of which the majority were self-limiting, followed by hyphema (n = 5, 10.4%) and tube exposure (n = 4, 8.3%).
CONCLUSION
The PGI demonstrated sustained IOP reduction and a reduction of medication burden at 3 years postoperatively.
More by Marcus Chun Jin Tan
View full profile →Two-Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma.
Outcomes of Stent Removal in Eyes With the Paul Glaucoma Implant With Intraluminal 6-0 Polypropylene.
Clinical Efficacy and Safety of the PAUL Glaucoma Implant: A Systematic Review and Meta-Analysis.
Top Research in Glaucoma Surgery
Browse all →Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up.
Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy.
Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results.
In the Knowledge Library
Discussion
Comments and discussion will appear here in a future update.